Phase I Study of Recombinant Human Interleukin-2 for Pediatric Malignancies: Feasibility of Outpatient Therapy. A Pediatric Oncology Group Study


    loading  Checking for direct PDF access through Ovid

Abstract

Summary:Published data indicate that when recombinant interleukin-2 (rIL-2) is administered to children as a 15-min i.v. bolus, doses of 18 x 106 IU/m2 are poorly tolerated, requiring intensive care unit (ICU) management of IL-2- induced hypotension. We administered rIL-2 as a 1- or 2-h i.v. infusion to 11 children with malignancies refractory to conventional therapy. IL-2 was given every Monday/ Wednesday/Friday for 3 weeks. Four children received 12 x 106 IU/m2/dose, four received 18 x 106 IU/m2/dose, and three received 24 x 106 IU/m2/dose (1 Cetus Unit=6 IU). Fever, chills, flushing, nausea, vomiting, transient weight gain, and oliguria were observed at all three dose levels (not dose-limiting toxicities). Cardiovascular toxicity was significantly reduced compared to the bolus regimen. Mild hypotension was observed at all three dose levels; however, there was no severe dose-limiting hypotension. Because of reduced cardiovascular toxicity, IL-2 was safely administered on an outpatient basis. This regimen induced marginal transient increases in natural killer cell activity and lymphokine-activated killer cell activity. No measurable clinical tumor response was observed in any of the 11 children. The maximum tolerated dose has not been reached. This regimen allows for a considerable cost reduction (outpatient care instead of ICU care) and safety, making further clinical trials on the use of IL-2 in children more feasible.

    loading  Loading Related Articles